What’s New

Announcement regarding Research Progress on New Compounds

Announcement regarding Development of New Cancer Gene Panel Test at Our Subsidiary Company, Cancer Precision Medicine, Inc.

Announcement regarding termination of out-licensing contract and agreement to transfer patent rights of antibodies

Announcement of Research for New Compounds

Announcement of the Presentation of Interim Results for Phase I Clinical Study of a Combination of OTSGC-A24 and Immune Checkpoint Inhibitor in Patients with Gastric Cancer

Publication of a paper describing Phase II study of cancer peptide vaccine S-588410 in urothelial carcinoma

Announcement of the press release from QST regarding the publication of 225Ac-labeled OTSA101

Poster presentation of OTSA101 research for cervical cancer at the 80th Annual Meeting of the Japanese Cancer Association

Publication of a paper describing the synergistic effect of OTS167 and FLT3 inhibitors on acute myeloid leukemia

Publication of a paper describing a phase 2 study of cancer vaccine OCV-C01 in patients with biliary tract cancer

Announcement of the presentation of results for Phase II study of S-588410 in bladder cancer at ASCO GU 2021

The announcement of the initiation of Phase I clinical study of OTS167 for breast cancer patients in Japan

Publication of a paper describing a phase 2 study of cancer vaccination therapy in patients with refractory/persistent cervical cancer and ovarian cancer

Publication of a paper describing a pilot study of peptide vaccines for patients with malignant glioma

The initiation of COVID-19 peptide vaccine R&D project

Publication of a paper describing the antitumor effect of MELK inhibitor OTS167 on ovarian cancer

The press release from Kindai University regarding Phase II cancer-specific peptide vaccine therapy (investigator-initiated clinical trial) for esophageal cancer patients

Publication of a scientific paper about liquid biopsy

Publication of a case study supported by Cancer Precision Medicine for the neoantigen and TCR repertoire analyses

Announcement of the press release from Keio University School of Medicine regarding the publication of immunotherapy for neurofibromatosis type 2 (NF2)